IC TARGETS

IC Targets is a biotechnology company focused on the discovery and development of novel antibody-based therapeutics for the treatment of cancer. The company utilizes a proprietary platform to identify "internalizing" cell surface targets that are specifically expressed on tumor cells, facilitating the efficient delivery of therapeutic payloads. By focusing on antibodies that are rapidly internalized, IC Targets aims to develop highly effective antibody-drug conjugates (ADCs) with improved safety profiles. The company's research originated from the University of California, San Francisco, and targets a variety of high-unmet-need solid tumors. Their approach combines advanced phage display technology with functional screening to bypass traditional target discovery limitations.